| Identification | Back Directory | [Name]
PF-01367338 | [CAS]
459868-92-9 | [Synonyms]
CS-47
Rubraca
AG14699
AG-014699
PF-01367338
Rucaparib(AG-01)
AG014699 phosphate
AG-014699 phosphate
AG 014699 phosphate
PF-01367338/AG14699
Rucaparib phosphate
Rucaparib(AG-014699)
PF01367338 phosphate
AG-014699 (Rucaparib)
AG-014699;PF-01367338
PF-01367338 USP/EP/BP
Rucaparib ( PF-01367338)
Rucaparib phosphate salt
AG-014447 (as free base)
AG-14699 (as phosphate salt)
AG014699;RUCAPARIB PHOSPHATE
Rucaparib phosphate AG-014699
Rucaparib (AG-014699) phosphate
AG 014699 - PF 01367338 | Rucaparib
Rucaparib (AG-014699 , PF-01367338)
Rucaparib phosphate (AG-14699, PF-01367338)
Rucaparib (AG-014699,PF-01367338) phosphate
Rucaparib (phosphate)(AG-014699,PF-01367338)
AG-14699 (AS PHOSPHATE SALT); AG-014447 (AS FREE BASE); RUCAPARIB; PF-01367338; AG014699;
8-Fluoro-2-(4-((methylamino)methyl)phenyl)-4,5-dihydro-1H-azepino[5,4,3-cd]indol-6(3H)-one pho
8-Fluoro-2-(4-((methylamino)methyl)phenyl)-4,5-dihydro-1H-azepino[5,4,3-cd]indol-6(3H)-one phosphate
8-fluoro-5-(4-((methylamino)methyl)phenyl)-2,3,4,6-tetrahydro-1H-azepino[5,4,3-cd]indol-1-onephosphate
8-fluoro-5-(4-((methylamino)methyl)phenyl)-3,4-dihydro-2H-azepino[5,4,3-cd]indol-1(6H)-one phosphoric acid
8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one phosphate
6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one, 8-fluoro-1,3,4,5-tetrahydro-2-[4-[(MethylaMino)Methyl]phenyl]-, phosphate (1:1)
RUCAPARIB PHOSPHATE;AG014699 PHOSPHATE;PF01367338 PHOSPHATE;AG 014699 PHOSPHATE;PF 01367338 PHOSPHATE;AG-014699 PHOSPHATE;PF-01367338 PHOSPHATE
AG14699 (AS PHOSPHATE SALT); AG 14699; AG-14699; AG014447 (AS FREE BASE); AG-014447; AG 014447; PF01367338; PF-01367338; PF 01367338; RUCAPARIB; RUBRACA;
AG 014699 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one phosphate
8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one phosphate Rucaparib(AG-014699) | [Molecular Formula]
C19H21FN3O5P | [MDL Number]
MFCD17010269 | [MOL File]
459868-92-9.mol | [Molecular Weight]
421.37 |
| Chemical Properties | Back Directory | [Melting point ]
>173°C (dec.) | [storage temp. ]
Sealed in dry,Room Temperature | [solubility ]
Soluble in DMSO (up to 25 mg/ml). | [form ]
Yellow solid. | [color ]
Yellow | [Stability:]
Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months. |
| Hazard Information | Back Directory | [Description]
Rucaparib phosphate (459868-92-9) is a potent (Ki<5 nM) PARP1 inhibitor.1?Cytotoxic to human cancer cells or xenograft tumors with mutated or epigenetically silenced BRCA1/2.2?Demonstrates antiproliferative effects in 26 out of 39 ovarian cancer cell lines.3?Synergizes with other anticancer agents such as topotecan, carboplatin, doxorubicin, paclitaxel,3 and temozolomide.4?Ameliorates the cardiotoxicity of doxorubicin.5?Recently approved for human use by the FDA. | [Uses]
PARP inhibitor oncolytic | [in vivo]
Rucaparib (AG014699) phosphate and AG14584 significantly increase Temozolomide toxicity. Rucaparib (1 mg/kg) phosphate significantly increases Temozolomide-induced body weight loss. Rucaparib (0.1 mg/kg) phosphate results in a 50% increase in the temozolomide-induced tumor growth delay[1].
Rucaparib (10 mg/kg for i.p. or 50, 150 mg/kg for p.o.; daily for 5 days per week for 6 weeks) phosphate significantly inhibits the growth of the tumor, and there is one complete tumor regression and two persistent partial regressions[2].
Rucaparib (150 mg/kg; p.o.; once per week for 6 weeks or three times per week for 6 weeks) phosphate has greatest antitumor effect with three complete regressions[2].
Rucaparib phosphate enhances the antitumor activity of temozolomide and indicates complete and sustained tumor regression in NB1691 and SHSY5Y xenografts[6].
| Animal Model: | Female athymic nude mice, implanted SW620 colorectal tumor cells (1 × 107 cells per animal) s.c.[1] | | Dosage: | 0.1 mg/kg in combination with Temozolomide (p.o., 200 mg/kg), 0.05, 0.15, and 0.5 mg/kg in combination with Temozolomide (p.o., 68 mg/kg) or 10 mg/kg | | Administration: | IP, single dose for 0.1 mg/kg and 10 mg/kg, five daily doses for 0-0.5 mg/kg | | Result: | Significantly increased Temozolomide toxicity, showed outstanding chemosensitization potency and caused enhancement of Temozolomide-induced tumor growth delay |
| Animal Model: | CD-1 nude mice bearing established Capan-1 xenografts[2] | | Dosage: | 10 mg/kg or 50, 100 and 150?mg/kg | | Administration: | IP for 10 mg/kg; PO for 50, 100 and 150?mg/kg, single dose (Pharmacokinetics) | | Result: | Parent drug was detectable in the plasma only at 30?min after 10?mg/kg i.p and up to 4?h for 50–150?mg/kg p.o.. Was still detectable in most mice receiving oral rucaparib at 3 days. Does not easily cross the plasma membrane. |
| Animal Model: | CD-1 nude mice bearing established Capan-1 xenografts[2] | | Dosage: | 10?mg/kg i.p. daily for 5 days per week for 6 weeks, 50 or 150?mg/kg p.o. daily × five weekly × six, 150?mg/kg p.o. once per week for 6 weeks or three times per week for 6 weeks, or 150?mg/kg p.o. daily for five days every 3 weeks | | Administration: | IP or PO | | Result: | 10?mg/kg i.p. significantly inhibited the growth of the tumor, daily oral administration at 150?mg/kg had an equivalent effect on tumor growth to 10?mg/kg i.p.. The schedule with the greatest antitumor effect was oral administration of 150?mg/kg on a once weekly schedule with three complete regressions. |
| Animal Model: | CD-1 nude mice, NB1691 and SHSY5Y xenografts[6] | | Dosage: | 1 mg/kg | | Administration: | IP, daily for 5 d in combination with Temozolomide (orally daily ×5 at a dose of 68 mg/kg) | | Result: | Enhanced the antitumor activity of Temozolomide and indicated complete and sustained tumor regression. |
| [IC 50]
PARP-1: 1.4 nM (Ki); PARP-2; PARP-3 | [References]
1) Thomas?et al.?(2007),?Preclinical selection of a n novel poly(ADP-ribose) polymerase inhibitor for clinical trial; Mol. Cancer Ther.,?6?945
2) Drew?et al.?(2011),?Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2; J. Natl. Cancer Inst.,?103?334
3) Ihnen?et al.?(2013),?Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer; Mol. Cancer Ther.,?12?1002
4) Plummer?et al.?(2013),?A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation; Cancer Chemother. Pharmacol.,?71?1191
5) Ali?et al.?(2011),?The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice; Mol. Cancer Ther.,?10?2320 |
|
|